Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.54 |
| ▸ | CCND1 | P24385 | 9/20 | 0.54 |
| ▸ | CCND2 | P30279 | 9/20 | 0.54 |
| ▸ | CCND3 | P30281 | 9/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25462029 | 0.80 | CDK4 (0.55) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL29861616 | 0.80 | CDK4 (0.55) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL6808415 | 0.79 | CDK4 (0.59) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL5264427 | 0.79 | CDK4 (0.54) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL4825502 | 0.78 | CDK4 (0.57) | CDK4CCND1CCND2CCND3MAPK8 | |
| Hydrochloric Acid SCHEMBL29862011 | 0.77 | CDK4 (0.52) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL6808956 | 0.77 | CDK4 (0.60) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL2262076 | 0.76 | CDK4 (0.67) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL5264100 | 0.76 | CDK4 (0.51) | CDK4CCND1CCND2CCND3MAPK8 | |
| SCHEMBL19231463 | 0.76 | CYP1A2 (0.62) | CDK4CCND1CCND2CCND3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | CDK4 98/4885CCND1 2208/4885CCND2 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.